TY - JOUR AU - Sihombing, David H. P. AU - Polii, Natalia C. I. AU - Panda, Agnes L. PY - 2021/04/12 Y2 - 2024/03/29 TI - Penggunaan Mineralocorticoid Receptor Antagonist pada Heart Failure Reduced Ejection Fraction JF - e-CliniC JA - eCl VL - 9 IS - 2 SE - Articles DO - 10.35790/ecl.v9i2.33144 UR - https://ejournal.unsrat.ac.id/v3/index.php/eclinic/article/view/33144 SP - 379-387 AB - <p><strong>Abstract:</strong> Heart failure reduction ejection fraction (HFrEF) is heart failure associated with decreased ejection fraction. It is characterized by abnormalities in cellular calcium regulation and changes in calcium kinetics that cause contraction changes in the myocardium. According to the European Society of Cardiology, mineralocorticoid receptor antagonist (MRA) is used as an adjunct drug when the first-line drugs are not sufficient to treat heart failure. This class of drugs has been shown to be very effective in use in HFrEF patients as shown in The Randomized Aldactone Evaluation Study (RALES), therefore, its use has been approved by the Food and Drug Administration (FDA). This study was aimed to analyze the effectiveness of MRA on HfrEF. This was a literature review study. The results showed that the use of MRA had significant benefits in reducing morbidity, mortality, and re-hospitalization in HFrEF patients. Improvements shown by the use of MRA included increased level of brain natriuretic peptide (BNP), improved NYHA classification, and decreased patient weight. A side effect that needs to be considered was hyperkalemia, whereas hypotensive effect was not of great concern because MRA was rarely reported to cause hypotension even when the initial systolic blood pressure is low. In conclusion, <em>mineralocorticoid receptor antagonist</em> is useful to improve the outome of HFrEF patients<em>.</em></p><p><strong>Keywords:</strong> heart failure, heart failure reduced ejection fraction (HFrEF), mineralocorticoid receptor antagonist (MRA)</p><p> </p><p><strong>Abstrak</strong>: <em>Heart Failure reduced Ejection Fraction </em>(HFrEF) merupakan gagal jantung disertai penurunan fraksi ejeksi. Kondisi ini ditandai dengan adanya kelainan regulasi kalsium seluler dan perubahan kinetika kalsium yang menyebabkan terjadinya perubahan kontraksi miokardium. Menurut <em>European Society of Cardiology</em><em>, mineralocorticoid receptor antagonist</em> (MRA) digunakan sebagai obat tambahan bila obat lini pertama tidak cukup untuk mengatasi gagal jantung. Obat golongan ini terbukti sangat efektif digunakan pada pasien HFrEF sebagaimana yang ditunjukkan pada penelitian <em>The Randomized Aldactone Evaluation Study</em> (RALES), sehingga penggunaannya telah disetujui oleh <em>Food and Drugs Administration</em> (FDA).<strong> </strong>Penelitian ini bertujuan untuk menganalisis efektifitas penggunaan MRA pada pasien HFrEF.<strong> </strong>Jenis penelitian ialah <em>literature review</em>. Hasil<strong> </strong>penelitian memperlihatkan bahwa penggunaan MRA memiliki manfaat yang bermakna untuk menurunkan morbiditas, mortalitas, dan rawat inap ulang pada pasien HFrEF. Perbaikan yang ditunjukkan oleh penggunaan MRA antara lain peningkatan kadar <em>Brain Natriuretic Peptide</em> (BNP), perbaikan klasifikasi NYHA, dan penurunan berat badan pasien. Efek samping yang perlu menjadi pertimbangan ialah hiperkalemia, sedangkan efek hipotensi tidak terlalu dikhawatirkan karena MRA dilaporkan jarang menyebabkan hipotensi bahkan ketika tekanan darah sistolik awal rendah. Simpulan penelitian ini ialah <em>mineralocorticoid receptor antagonist</em> bermanfaat untuk memperbaiki luaran<em> </em>pada pasien HFrEF<em>.</em></p><p><strong>Kata kunci: </strong>gagal jantung, <em>heart failure reduced ejection fraction</em> (HFrEF), <em>mineralocorticoid, receptor antagonist</em> (MRA)</p> ER -